Ahead Therapeutics ^Company

Ahead Therapeutics is a start-up biotech company that uses a proprietary technology to develop treatments for different auto-immune disorders. Ahead Therapeutics has developed an innovative solution based on the use of PS-liposomes containing auto-autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, thereby interrupting the autoimmune reaction. Simply by changing the encapsulated auto-antigen, Ahead’s technology can address the treatment of different auto-immune diseases: Type 1 Diabetes; Multiple Sclerosis; and Celiac Diseases, among others. Despite its potential for preventive use, Ahead’s treatment is mainly foreseen as a reverse therapeutic vaccine, leading to a permanent cure of the disease. Ahead Therapeutics’ solution has several competitive advantages derived from its biomimetic/physiologic mechanism of action: long-lasting/permanent effect, non-systemic immunosuppressive, no secondary effects/toxicity, low-cost production, and complementarity with other therapies. The liposome-based platform has already been validated in animal models and preclinical non-regulatory assays are being completed for some indications. The next steps are pre-clinical regulatory and to expand the pipeline with new proof of concept based on Ahead’s technology for additional indications. Autoimmune diseases affect 5-10% of the global population and require chronic palliative treatments, resulting in lower quality of life and huge costs for society.